---
title: Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening
nct_id: NCT02038283
overall_status: COMPLETED
sponsor: The University of Hong Kong
study_type: OBSERVATIONAL
primary_condition: Colorectal Neoplasms
countries: Hong Kong
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02038283.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02038283"
ct_last_update_post_date: 2016-05-16
last_seen_at: "2026-05-12T07:06:14.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening

**Official Title:** A Study on Health-related Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening in Hong Kong

**NCT ID:** [NCT02038283](https://clinicaltrials.gov/study/NCT02038283)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 587
- **Lead Sponsor:** The University of Hong Kong
- **Collaborators:** Queen Mary Hospital, Hong Kong, Food and Health Bureau, Hong Kong
- **Conditions:** Colorectal Neoplasms
- **Start Date:** 2009-10
- **Completion Date:** 2012-06
- **CT.gov Last Update:** 2016-05-16

## Brief Summary

Introduction: Colorectal cancer (CRC) is the second most common cancer among Chinese in Hong Kong and the second leading cause of cancer death in this population. Several screening strategies has been associated with improved survival and may affect patients' health-related quality of life (HRQOL). HRQOL impact should be used to adjust for survival in terms of quality adjusted life years (QALY) in the evaluation of cost-effectiveness of any intervention including screening.

Objectives: to determine the HRQOL and health preference of patients with different stages of colorectal neoplasm, and to determine the most cost-effective CRC screening strategy for increasing QALYs.

Design and Subjects: A longitudinal survey to collect data on HRQOL associated with colorectal neoplasm for Markov modeling on cost-effectiveness of CRC screening. A stratified sample of 420 patients with colorectal polyps and different stages of CRC will be recruited from colorectal clinics of Queen Mary Hospital for health preference and HRQOL assessment. The HRQOL over time will be measured at baseline, 6 and 12 months later. Health preference data will be integrated with cost and effectiveness data obtained from the literature to determine the cost-effectiveness of currently recommended CRC screening strategies by Markov modeling.

Main outcome measures: The primary outcome measure is the SF-6D health preference value and QALYs. Secondary outcomes are the SF-12v2 and FACT-C scores. The outcomes will be compared between patients with different stages of colorectal neoplasm. Markov modeling study will estimate the expected QALYs gained and incremental cost-effectiveness ratio for each CRC screening strategy.

Results: The study will provide information on HRQOL of patients with colorectal neoplasm to guide health services. The Markov Model will identify the most cost-effective CRC screening strategy for Hong Kong Chinese, which can inform policy makers and the public for the prevention of CRC of the population.

## Detailed Description

The aims are to determine the HRQOL and health preference (utility) of different stages of colorectal neoplasm in order to evaluate the cost-effectiveness of different CRC screening strategies for the Chinese population in Hong Kong.

The specific objectives are:

1. To determine the HRQOL preference values of patients in different stage of colorectal neoplasm in order to estimate the quality of life adjustment applicable to each stage of colorectal neoplasm.
2. To evaluate the HRQOL of patients with colorectal neoplasm in order to find out their concerns and needs.
3. To find out whether HRQOL preference of people with colorectal neoplasm changes with time.
4. To determine the expected life years gained from the reduction in the incidence and mortality rates of CRC for each CRC screening strategy base on literature review.
5. To determine the QALY gained from each CRC strategy by combining the preference value with life years gained.
6. To identify the most cost-effective CRC screening strategy and to determine the incremental cost per additional QALY gained compared to no screening, by Markov modelling.

The study hypotheses are:

1. Patients with colorectal neoplasm including those with polyps have lower HRQOL than the general population.
2. There is a gradient reduction in HRQOL preference among patients with different stages colorectal neoplasm from polyp to metastatic cancer.
3. HRQOL preference of patients with colorectal neoplasm is stable if there is no change in the disease stage.
4. Annual I-FOBT is the most cost-effective CRC screening strategy for the Chinese population in Hong Kong.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age 18 years or above
* Have life expectancy of at least 6 months
* Have confirmed diagnosis of any of the following colorectal neoplasm classified by the screening surveillance guideline and UICC/AJCC (TNM) staging system
* Have given consent to take part in the study

Exclusion Criteria:

* Inability to understand or communicate in Cantonese or Chinese
* Significant cognitive impairment judged by the doctor to be unable to answer the questionnaire
* Too ill to carry out an interview
* Refuse to give consent
```

## Arms

- **Low-risk Colorectal Polyps** — ≤2 adenomas or 3-4 adenomas all of which are \<1cm
- **High-risk Colorectal Polyps** — ≥5 adenomas or ≥3 adenomas at least one of which is ≥1cm
- **Stage I CRC** — at least six months since diagnosis of Stage I CRC
- **Stage II CRC** — at least six months since diagnosis of Stage II CRC
- **Stage III CRC** — at least six months since diagnosis of Stage III CRC
- **Stage IV CRC** — at least six months since diagnosis of Stage IV CRC

## Primary Outcomes

- **SF-6D Preference-based Value** _(time frame: Twelve months)_ — HRQOL preference value measured by The Chinese (HK) SF-6D Health Survey was calculated by the HK population specific algorithm. It ranges from 0 (death) to 1 (perfect health).
- **Quality-adjusted life years for each screening strategy** _(time frame: Baseline)_ — The effectiveness of CRC screening is quantified by Quality-adjusted life years, which was calculated as the product of average duration of each health state (including no illness) and the SF-6D preference value for that particular health state.
- **Direct Health Care Costs for each CRC screening strategy** _(time frame: Baseline)_ — The direct health care costs of different CRC screening strategies and treatments of different stages of CRC were estimated using the costs published by the Government Gazette.

## Secondary Outcomes

- **HRQOL by SF-12v2 and FACT-C** _(time frame: Twelve months)_
- **Health Service Utilizations** _(time frame: Baseline)_
- **Factors Associated with HRQOL** _(time frame: Baseline)_

## Locations (3)

- Department of Clinical Oncology, Faculty of Medicine, The University of Hong Kong, Hong Kong Island, Hong Kong
- Department of Medicine, Queen Mary Hospital, Hong Kong Island, Hong Kong
- Department of Surgery, Faculty of Medicine, The University of Hong Kong, Hong Kong Island, Hong Kong

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of clinical oncology, faculty of medicine, the university of hong kong|hong kong island||hong kong` — added _(2026-05-12)_
- `locations.department of medicine, queen mary hospital|hong kong island||hong kong` — added _(2026-05-12)_
- `locations.department of surgery, faculty of medicine, the university of hong kong|hong kong island||hong kong` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02038283.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02038283*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*